

VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES

15-17 June 2020, University of Latvia, Riga, Latvia

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR VLPNPV 2020

Virus-like particles are supra-molecular assemblages incorporating key immunologic features of viruses which include repetitive surfaces, particulate structures with potential for induction of innate immunity through activation of pathogen-associated molecular-pattern recognition receptors. They carry no replicative genetic information and can be produced in heterologous expression systems at large scale. Virus-like particles thus represent a safe and effective vaccine platform with potential to induce potent B- and T-cell responses. In addition to being effective vaccines against the corresponding viruses from which they are derived, virus-like particles can also be used to present foreign epitopes to the immune system. This can be achieved by genetic fusion or chemical conjugation. This technological innovation has greatly broadened the scope of their use, from immunizing against microbial pathogens to immunotherapy for chronic diseases. Towards this end, virus-like particles have been used to induce auto-antibodies to disease-associated self-molecules involved in chronic diseases, such as hypertension and Alzheimer's disease. The recognition of the potent immunogenicity and commercial potential for virus-like particles has greatly accelerated research and development activities. During the last decade, two prophylactic virus-like particle vaccines have been registered for human use, while another 12 vaccines entered clinical development.

VLPNPV 2020 is the sixth meeting in this new series, the first being held in Cannes in 2012, for international researchers working on Virus-Like Particles (VLPs) the multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, and Nano-Particles potentially yielding safer and cheaper vaccine candidates. A small number of prophylactic VLP-based vaccines are currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.'s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests. This meeting will focus on the essential role of VLP technology in new-generation vaccines against prevalent and emergent diseases. The implications of large-scale VLP production will be important for process control, monitorization and optimization. VLP-based and NP-based vaccines updates will be presented with the latest results from clinical trials and the recent developments in chimeric VLP-based technology for either therapeutic or prophylactic vaccination.

VLPNPV 2020 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups. Abstracts for possible oral and/or poster presentation are invited by the VLPNPV 2020 Scientific Advisory Panel – please refer over page for details.

SCIENTIFIC ADVISORY PANEL

Conference Chairman: Kaspars Tars (*Biomedical Research & Study Center, University of Latvia, Riga, Latvia*)

Martin Bachmann (*University of Bern, Bern, Switzerland*)

John Dangerfield (*Anovasia Pte Ltd, Singapore*)

Rob Lambkin-Williams (*hVIVO Ltd, London, UK*)

Kaspars Tars (*Biomedical Research and Study Center, Riga, Latvia*)

Sebastian Maurer-Stroh (*A-Star, Singapore*)

Jean-Christophe Audonnet (*Meril, Lyon, France*)

Bryce Chackerian (*University of New Mexico, Albuquerque, New Mexico, USA*)

Marc-Andre D'Aoust (*Medicago Inc., Quebec, Canada*)

Melissa M. Herbst-Kralovetz (*University of Arizona, Phoenix, Arizona, USA*)

George Lomonosoff (*John Innes Centre, Norwich, UK*)

Ann Meyers (*University of Cape Town, South Africa*)

Peter Moran (*ACM Biolabs, Singapore*)

Peter Pushko (*Medigen Inc., Frederick, Maryland, USA*)

Ted Ross (*University of Georgia, Athens, Georgia, USA*)

Brian Ward (*McGill University, Montreal, Quebec, Canada*)

Vidadi Yusibov (*Fraunhofer USA, Newark, Delaware, USA*)

Richard Compans (*Emory University, Atlanta, Georgia, USA*)

Trudy Morrison (*University of Massachusetts, Worcester, Massachusetts, USA*)

Hans Netter (*The Peter Doherty Institute, Melbourne Health, Melbourne, Australia*)

Linda Lua (*The University of Queensland, Brisbane, Queensland, Australia*)

Madhavan Nallani (*ACM Biolabs, Singapore*)

Martin Eisenhawer (*WHO, Geneva, Switzerland*)

CONFERENCE SCOPE

Virus-Like Particle Vaccines · VLP Vaccine Manufacturing · Nano-Particles and Nano-Particulate Vaccines

VLP Platforms as Delivery Systems for Therapeutics, Imaging and Antigen Presentation







Structure (non-enveloped, enveloped and synthetic) · Formulation and Stability of VLP and Nano-Particulate Vaccines and Adjuvants

Delivery Systems (including Microneedles) · VLP Expression Systems (Baculovirus, Cell Culture, Yeast, Plants)

Safety and Regulatory Issues (regulation of expression systems) · HepB · HPV · Influenza · Developing VLP Candidates · Clinical Trials Updates

ISCOMs & ISCOMATRIX · Chitosan Particles · Liposomes · VLPs as Protein Delivery Systems · VLPs for Drug Delivery

Novel Applications (eg Cell-Free Synthesis) · Nanotechnology Approaches (Non-Conventional VLPs) · Particulate-Based Vaccines



Abstract Submissions

The VLPNPV 2020 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during VLPNPV 2020. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (VLPNPV 2020 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 13th December 2019**. Authors will be informed of the status of their contribution(s) in January 2020.

Closing date for submissions intended for poster presentation: **Friday 15th May 2020**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to VLPNPV 2020. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at VLPNPV 2020. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on VLPNPV 2020
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- My organisation is interested in sponsoring VLPNPV 2020 Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- MODERN VACCINES ADJUVANTS & DELIVERY SYSTEMS** – 9-11 September 2019, Bern, Switzerland
- VACCINES FOR ENTERIC DISEASES** – 16-18 October 2019, Lausanne, Switzerland
- SKIN VACCINATION SUMMIT 2020** – 17-19 March 2020, Edinburgh, Scotland, UK
- UNIVERSAL INFLUENZA VACCINES** – 29-30 April – 1 May 2020, Oxford, UK

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, VLPNPV 2020, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 E-mail: jherriot@meetingsmgmt.u-net.com Website: www.meetingsmanagement.com/vlpnpv_2020